Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study describes a patient who developed mild eosinophilia and a skin rash after starting clozapine, which resolved without discontinuing the medication.

This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study found that oral spironolactone improved certain biomarkers in central serous chorioretinopathy patients, but recurrence, especially in older patients, was relatively common.

This study found that sodium valproate significantly reduced seizure frequency by over 50% in about 70% of patients with generalized seizures but was less effective for partial seizures.

This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that Romanian men with schizophrenia had better mental functioning than women, and atypical antipsychotics were associated with improved quality of life across various dimensions for all patients.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This article reviews the use of Serenoa repens for androgenetic alopecia and highlights a lack of evidence supporting its efficacy, calling for larger clinical trials.

This article discusses the potential for severe adverse cutaneous drug reactions with mood-stabilizing agents, emphasizing the importance of monitoring and patient communication, but reports no new clinical findings.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study is designed to explore how circadian rhythms are affected by obesity and mental health conditions, such as schizophrenia and bipolar disorder, using biological and lifestyle data from independently living adults.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

Sulfasalazine can cause severe allergic reactions leading to long-term autoimmune issues like hair loss and skin discoloration.

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This article discusses Serenoa repens for androgenetic alopecia and reports no strong evidence of its effectiveness, emphasizing the need for larger clinical trials.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This article reviews the implications of post-SSRI sexual dysfunction syndrome and underscores the need for further epidemiological research to understand the condition and potential treatments, without offering new results.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.